Abstract
Due to its high mortality rate, heart failure (HF) presents a substantial worldwide health burden that calls for efficient treatment approaches. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become essential treatments for heart failure in all left ventricular ejection fraction (LVEF) levels. Their processes, which include enhanced metabolic efficiency and ventricular loading circumstances, present encouraging results. The effectiveness of SGLT2 inhibitors, dapagliflozin and empagliflozin, in lowering cardiovascular mortality and heart failure hospitalizations in heart failure patients with reduced, mildly reduced, and preserved ejection fraction has been shown in several clinical trials, including DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER. These results represent a revolutionary development in the treatment of HF, emphasizing the use of SGLT2 inhibitors in comprehensive treatments, regardless of renal function or diabetes state.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
